Neurometabolite levels in antipsychotic-naive/free patients with schizophrenia: A systematic review and meta-analysis of $^{\textrm{1}}$H-MRS studies. July, 2018. Paper abstract bibtex Author Names: Iwata Y.,Nakajima S.,Plitman E.,Mihashi Y.,Caravaggio F.,Chung J.K.,Kim J.,Gerretsen P.,Mimura M.,Remington G.,Graff-Guerrero A. Database Source: Embase Journal Title: Progress in Neuro-Psychopharmacology and Biological Psychiatry Article Title: Neurometabolite levels in antipsychotic-naive/free patients with schizophrenia: A systematic review and meta-analysis of $^{\textrm{1}}$H-MRS studies Year: 2018 Issue: Volume: 86 Abstract: Background: Studies using proton magnetic resonance spectroscopy ($^{\textrm{1}}$H-MRS) have reported altered neurometabolite levels in patients with schizophrenia. However, results are possibly confounded by the influence of antipsychotic (AP). Thus, this meta-analysis aimed to examine neurometabolite levels in AP-naive/free patients with schizophrenia. Methods: A literature search was conducted using Embase, Medline, and PsycINFO to identify studies that compared neurometabolite levels in AP-naive/free patients with schizophrenia to healthy controls (HCs). Eight neurometabolites (glutamate, glutamine, glutamate + glutamine, N-acetylaspartate [NAA], choline, creatine, myo-inositol, and gamma-Aminobutyric acid [GABA]) and seven regions of interest (ROI; medial prefrontal cortex, dorsolateral prefrontal cortex, frontal white matter, occipital lobe, basal ganglia, hippocampus/medial temporal lobe, and thalamus) were examined. Results: Twenty-one studies (N = 1281) were included in the analysis. The results showed lower thalamic NAA levels (3 studies, n = 174, effect size = -0.56, P = 0.0005) in the patient group. No group differences were identified for other neurometabolites. Conclusions: Our findings suggest that impaired neuronal integrity in the thalamus may be a potential trait maker in the early stages of schizophrenia.\textlessbr/\textgreaterCopyright © 2018 Elsevier Inc.
@article{noauthor_neurometabolite_2018,
title = {Neurometabolite levels in antipsychotic-naive/free patients with schizophrenia: {A} systematic review and meta-analysis of $^{\textrm{1}}${H}-{MRS} studies},
copyright = {Copyright (c) Wolters Kluwer 2018},
url = {http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&MODE=ovid&PAGE=fulltext&NEWS=n&D=emedx%2cemexb&AUTOALERT=244511040%7c1},
abstract = {Author Names: Iwata Y.,Nakajima S.,Plitman E.,Mihashi Y.,Caravaggio F.,Chung J.K.,Kim J.,Gerretsen P.,Mimura M.,Remington G.,Graff-Guerrero A. Database Source: Embase Journal Title: Progress in Neuro-Psychopharmacology and Biological Psychiatry Article Title: Neurometabolite levels in antipsychotic-naive/free patients with schizophrenia: A systematic review and meta-analysis of $^{\textrm{1}}$H-MRS studies Year: 2018 Issue: Volume: 86 Abstract: Background: Studies using proton magnetic resonance spectroscopy ($^{\textrm{1}}$H-MRS) have reported altered neurometabolite levels in patients with schizophrenia. However, results are possibly confounded by the influence of antipsychotic (AP). Thus, this meta-analysis aimed to examine neurometabolite levels in AP-naive/free patients with schizophrenia. Methods: A literature search was conducted using Embase, Medline, and PsycINFO to identify studies that compared neurometabolite levels in AP-naive/free patients with schizophrenia to healthy controls (HCs). Eight neurometabolites (glutamate, glutamine, glutamate + glutamine, N-acetylaspartate [NAA], choline, creatine, myo-inositol, and gamma-Aminobutyric acid [GABA]) and seven regions of interest (ROI; medial prefrontal cortex, dorsolateral prefrontal cortex, frontal white matter, occipital lobe, basal ganglia, hippocampus/medial temporal lobe, and thalamus) were examined. Results: Twenty-one studies (N = 1281) were included in the analysis. The results showed lower thalamic NAA levels (3 studies, n = 174, effect size = -0.56, P = 0.0005) in the patient group. No group differences were identified for other neurometabolites. Conclusions: Our findings suggest that impaired neuronal integrity in the thalamus may be a potential trait maker in the early stages of schizophrenia.{\textless}br/{\textgreater}Copyright \&\#xa9; 2018 Elsevier Inc.},
month = jul,
year = {2018},
}
Downloads: 0
{"_id":"3CmB6emzcAXq96u4f","bibbaseid":"anonymous-neurometabolitelevelsinantipsychoticnaivefreepatientswithschizophreniaasystematicreviewandmetaanalysisoftextrm1hmrsstudies-2018","bibdata":{"bibtype":"article","type":"article","title":"Neurometabolite levels in antipsychotic-naive/free patients with schizophrenia: A systematic review and meta-analysis of $^{\\textrm{1}}$H-MRS studies","copyright":"Copyright (c) Wolters Kluwer 2018","url":"http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&MODE=ovid&PAGE=fulltext&NEWS=n&D=emedx%2cemexb&AUTOALERT=244511040%7c1","abstract":"Author Names: Iwata Y.,Nakajima S.,Plitman E.,Mihashi Y.,Caravaggio F.,Chung J.K.,Kim J.,Gerretsen P.,Mimura M.,Remington G.,Graff-Guerrero A. Database Source: Embase Journal Title: Progress in Neuro-Psychopharmacology and Biological Psychiatry Article Title: Neurometabolite levels in antipsychotic-naive/free patients with schizophrenia: A systematic review and meta-analysis of $^{\\textrm{1}}$H-MRS studies Year: 2018 Issue: Volume: 86 Abstract: Background: Studies using proton magnetic resonance spectroscopy ($^{\\textrm{1}}$H-MRS) have reported altered neurometabolite levels in patients with schizophrenia. However, results are possibly confounded by the influence of antipsychotic (AP). Thus, this meta-analysis aimed to examine neurometabolite levels in AP-naive/free patients with schizophrenia. Methods: A literature search was conducted using Embase, Medline, and PsycINFO to identify studies that compared neurometabolite levels in AP-naive/free patients with schizophrenia to healthy controls (HCs). Eight neurometabolites (glutamate, glutamine, glutamate + glutamine, N-acetylaspartate [NAA], choline, creatine, myo-inositol, and gamma-Aminobutyric acid [GABA]) and seven regions of interest (ROI; medial prefrontal cortex, dorsolateral prefrontal cortex, frontal white matter, occipital lobe, basal ganglia, hippocampus/medial temporal lobe, and thalamus) were examined. Results: Twenty-one studies (N = 1281) were included in the analysis. The results showed lower thalamic NAA levels (3 studies, n = 174, effect size = -0.56, P = 0.0005) in the patient group. No group differences were identified for other neurometabolites. Conclusions: Our findings suggest that impaired neuronal integrity in the thalamus may be a potential trait maker in the early stages of schizophrenia.\\textlessbr/\\textgreaterCopyright © 2018 Elsevier Inc.","month":"July","year":"2018","bibtex":"@article{noauthor_neurometabolite_2018,\n\ttitle = {Neurometabolite levels in antipsychotic-naive/free patients with schizophrenia: {A} systematic review and meta-analysis of $^{\\textrm{1}}${H}-{MRS} studies},\n\tcopyright = {Copyright (c) Wolters Kluwer 2018},\n\turl = {http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&MODE=ovid&PAGE=fulltext&NEWS=n&D=emedx%2cemexb&AUTOALERT=244511040%7c1},\n\tabstract = {Author Names: Iwata Y.,Nakajima S.,Plitman E.,Mihashi Y.,Caravaggio F.,Chung J.K.,Kim J.,Gerretsen P.,Mimura M.,Remington G.,Graff-Guerrero A. Database Source: Embase Journal Title: Progress in Neuro-Psychopharmacology and Biological Psychiatry Article Title: Neurometabolite levels in antipsychotic-naive/free patients with schizophrenia: A systematic review and meta-analysis of $^{\\textrm{1}}$H-MRS studies Year: 2018 Issue: Volume: 86 Abstract: Background: Studies using proton magnetic resonance spectroscopy ($^{\\textrm{1}}$H-MRS) have reported altered neurometabolite levels in patients with schizophrenia. However, results are possibly confounded by the influence of antipsychotic (AP). Thus, this meta-analysis aimed to examine neurometabolite levels in AP-naive/free patients with schizophrenia. Methods: A literature search was conducted using Embase, Medline, and PsycINFO to identify studies that compared neurometabolite levels in AP-naive/free patients with schizophrenia to healthy controls (HCs). Eight neurometabolites (glutamate, glutamine, glutamate + glutamine, N-acetylaspartate [NAA], choline, creatine, myo-inositol, and gamma-Aminobutyric acid [GABA]) and seven regions of interest (ROI; medial prefrontal cortex, dorsolateral prefrontal cortex, frontal white matter, occipital lobe, basal ganglia, hippocampus/medial temporal lobe, and thalamus) were examined. Results: Twenty-one studies (N = 1281) were included in the analysis. The results showed lower thalamic NAA levels (3 studies, n = 174, effect size = -0.56, P = 0.0005) in the patient group. No group differences were identified for other neurometabolites. Conclusions: Our findings suggest that impaired neuronal integrity in the thalamus may be a potential trait maker in the early stages of schizophrenia.{\\textless}br/{\\textgreater}Copyright \\&\\#xa9; 2018 Elsevier Inc.},\n\tmonth = jul,\n\tyear = {2018},\n}\n\n","key":"noauthor_neurometabolite_2018","id":"noauthor_neurometabolite_2018","bibbaseid":"anonymous-neurometabolitelevelsinantipsychoticnaivefreepatientswithschizophreniaasystematicreviewandmetaanalysisoftextrm1hmrsstudies-2018","role":"","urls":{"Paper":"http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&MODE=ovid&PAGE=fulltext&NEWS=n&D=emedx%2cemexb&AUTOALERT=244511040%7c1"},"metadata":{"authorlinks":{}},"html":""},"bibtype":"article","biburl":"https://bibbase.org/zotero/CECTC","dataSources":["WJssAw9LjPNgXmhEE"],"keywords":[],"search_terms":["neurometabolite","levels","antipsychotic","naive","free","patients","schizophrenia","systematic","review","meta","analysis","textrm","mrs","studies"],"title":"Neurometabolite levels in antipsychotic-naive/free patients with schizophrenia: A systematic review and meta-analysis of $^{\\textrm{1}}$H-MRS studies","year":2018}